James Xue, Founder and CEO of CANbridge to Attend Cancer Advance Boston Conference


James Xue, PhD,MBA, Founder and CEO of CANbridge will attend Cancer Advance Boston Conference to be held at Joseph B. Martin Conference Center, Harvard Medical School on September 30, 2014.

 The Conference is part of Boston Biotech Conferences exclusive thought-leader forums for senior bio-pharma executives.  The invitation-only, off-the-record forums bring together the past, present and future leaders in the biotechnology community to network, exchange ideas and share insights into the industry's challenges and opportunities.  This year's topic of Cancer Advance Boston is "Focus on Innovation".


About CANbridge Life Sciences

CANbridge Life Sciences, Ltd. is a bio-pharmaceutical company accelerating development and commercialization of specialty healthcare products for serious and critical medical conditions in China and North Asia (Korea and Taiwan).  CANbridge develops partnerships with Western bio-pharmaceutical companies with clinical-stage pharmaceutical, medical device or diagnostic products that are either unavailable in China/North Asia or address medical needs that are underserved in the region. CANbridge also licenses or obtains exclusive rights to commercialize drug and device products that are approved in their home markets for commercialization in China and North Asia.   CANbridge has an exclusive licensing agreement with U.S.-based Azaya Therapeutics, Inc., to develop and commercialize ATI-1123 in China, for the treatment of non-small cell lung cancer and other solid tumors. CANbridge also has an agreement with EUSA Pharma, a Jazz Pharmaceuticals company, to commercialize Caphosol® in China for the prevention and treatment of oral mucositis caused by cancer treatments.

Led and backed by a highly-seasoned executive team, with extensive Chinese drug development experience, CANbridge has the capability to select, acquire, develop and commercialize future therapeutics and diagnostics targeting the unmet medical needs of Chinese and East Asian patients with serious or critical conditions.

CANbridge is privately-held and headquartered in Beijing, China.  For more on CANbridge Life Sciences, please go to www.canbridgepharma.com.